

I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

Claim 1-34. (Cancelled)

Claim 35. (Currently Amended) A drug packaging system comprising packaging material ~~containing comprising therein combined prescription drug therapy comprising~~ one or more unit dosage forms of ~~lansiprazole~~ lansoprazole or a pharmaceutically acceptable salt thereof and one or more unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof; ~~and indicia that provides dosing information for administering the lansoprazole or pharmaceutically acceptable salt thereof and naproxen or pharmaceutically acceptable salt thereof.~~

Claim 36. (New) The drug packaging system of claim 35, wherein each unit dosage form is independently selected from the group consisting of a tablet, capsule, gel cap, and a caplet.

Claim 37. (New) The drug packaging system of claim 35, wherein said system comprises unit doses for up to 28 days.

Claim 38. (New) The drug packaging system of claim 35, wherein said system comprises unit doses for 7-14 days.

Claim 39. (New) The drug packaging system of claim 35, wherein the unit dosage forms containing lansoprazole or a pharmaceutically acceptable salt thereof are capsules.

Claim 40. (New) The drug packaging system of claim 35, wherein the unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof are tablets.

Claim 41. (New) The drug packaging system of claim 3, wherein the unit dosage forms containing lansoprazole comprise 15 mg lansoprazole.

Claim 42. (New) The drug packaging system of claim 35, wherein the unit dosage forms containing naproxen comprise 500 mg naproxen.

Claim 43. (New) The drug packaging system of claim 35, wherein the packaging material comprises a blister package comprising:

(a) a first set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of lansoprazole or pharmaceutically acceptable salt thereof, and

(b) a second set of rupturable substrates and a layer forming blisters over each of the rupturable substrates; each of the blisters containing one of said unit dosage forms of naproxen or a pharmaceutically acceptable salt thereof.

Claim 44. (New) A method of treating a disease or condition comprising administering to a patient, one or more unit dosage forms of lansoprazole or a pharmaceutically acceptable salt thereof and one or more unit dosage forms containing naproxen or a pharmaceutically acceptable salt thereof, from the system of claim 35.